SARS-CoV-2-IgM/IgG-Test-Kit(Immunochromatographic-Assay) |
EGIVD008 |
EnoGene |
CE-recogniton-IVD |
EUR 350 |
Description: CE recogniton IVD |
Human IgG antibody Laboratories manufactures the comprar test rapido anticuerpos sars-cv2 reagents distributed by Genprice. The Comprar Test Rapido Anticuerpos Sars-Cv2 reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS Test. Other Comprar products are available in stock. Specificity: Comprar Category: Test Group: Rapido Anticuerpos
COX (Coxsackievirus Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of COX (Coxsackievirus Antibody IgG) |
RV (Rubella Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of RV (Rubella Antibody IgG) |
CMV (Cytomegalovirus Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of CMV (Cytomegalovirus Antibody IgG) |
ACA (Anticardiolipin Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of ACA (Anticardiolipin Antibody IgG) |
TOX (Toxoplasma Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of TOX (Toxoplasma Antibody IgG) |
ANA (Antinuclear Antibody IgG) ELISA test |
Biobase |
96T/Box |
Ask for price |
|
Description: ELISA based test for quantitative detection of ANA (Antinuclear Antibody IgG) |
SARS-CoV-2 Rapid Antigen Test Nasal |
Roche Diagnostics |
25 Tests/Kit |
EUR 112.8 |
|
Description: The SARS-CoV-2 Rapid Antigen Test is a lateral fl ow rapid chromatographic immunoassay for the qualitative detection of nucleocapsid antigen to SARS-CoV-2 present in human nasal samples. This test is intended for use as an aid in detection of SARS-CoV-2 infection in individuals suspected of COVID-19 with clinical symptoms onset within 5 days. Results are for the identification of SARS-CoV-2 nucleocapsid antigen. Antigen is generally detectable in human nasal swab samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co- infection with other viruses. The agent detected may not be the definite cause of disease. Negative results should be treated as presumptive, and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19, and confirmed with a molecular assay, if necessary, for patient management. The SARS-CoV-2 Rapid Antigen Test is intended for use in laboratory or POC settings by healthcare professionals, or self-collection under the supervision of a healthcare worke |
Rapido Anticuerpos information
Brucella Antibody Rapid Test Kit |
abx092069-40tests |
Abbexa |
40 tests |
EUR 427.2 |
|
Melamine Rapid Test Kit |
abx092011-50tests |
Abbexa |
50 tests |
EUR 444 |
|